Genmab

	10/11 22:12 af bikube	Jep
	10/11 22:12 af Stroka	Er de blevet solgt i dag?
	10/11 22:09 af bikube	Så er der høstet warrants igen 47400.
	10/11 19:43 af Mogan	@Klarussen, Tak for det. Godt gået med timingen gennem tiderne vedr. køb/salg.
	10/11 19:21 af Legolas23	NBI er en indikator og virker ikke ind på Genmab.
	10/11 19:13 af Helge Larsen/PI-redaktør	NBI: (link)
	10/11 18:55 af Klarussen	Men vi bevarer det kølige overblik ;-)
	10/11 18:45 af Helge Larsen/PI-redaktør	Aktier: USA-frygtindeks ligger højt, men langt fra corona-top(link)
	10/11 18:40 af Klarussen	Har været inde og ude af Genmab en del gange, og tjent godt, men ville ønske jeg bare havde holdt fast fra starten og haft Helges kølige overblik ;-)
	10/11 18:40 af Klarussen	@Mogan, jeg er knap 100% kontant, solgte ud før præsidentvalget i US. Har ikke haft Genmab nogle måneder og venter på godt entrypoint. Tror vi skal længere ned i hele markedet , 2150 er bare et fiktivt tal, men i det område køber jeg gerne igen. Tror meget stærkt på Genmab på den lange bane.
	10/11 18:33 af E L	(and sometimes then should be than ;-) )
	10/11 18:31 af E L	(and that he has a lot more share then we do ;-) )
	10/11 18:31 af E L	@GB 17:06 don't forget that he always knows more then we do
	10/11 18:26 af E L	Jan can be quite good at not answering if he doesnt want ;)
	10/11 18:26 af E L	i think he also asked Jan in a QA about dr5 / liver tox, but Jan didnt really answer
	10/11 18:23 af E L	"29/3 09:33 af Sukkeralf The problem with 4-1BB was liver tox if I remember what Jan said at some point - so with these new attempts where you only get them attivated in the microenviroment of the solid tumours it should avoid liver tox"
	10/11 18:20 af Bulder	didn't winkel comment on the liver-issue recently? or was that dr5/dr5?
	10/11 18:16 af E L	yes, ok, me too
	10/11 18:16 af E L	and you can be sure Genmab does know that data
	10/11 18:16 af Bulder	It's based on the conclusion in the abstract
	10/11 18:16 af E L	or dose and toxicity for that matter, we saw no data on that i think
	10/11 18:15 af E L	that would make sense. maybe that is something we can hear about on friday. But from the data we saw today, i found it hard to find a strong correlation between dose and efficacy
	10/11 18:14 af GeorgeBest	Nordea think the liver side-effects may hinder going to high doses!
	10/11 18:14 af E L	and it seems manageable

	10/11 18:14 af E L	because before, i was worried about liver tox
	10/11 18:13 af E L	regarding safety Bulder , is that based on the data we just saw?
	10/11 18:12 af E L	yes, maybe. but i don't expect new data @AaBforever , more of a deep dive into what we know and more explanation
	10/11 18:12 af gdn55	Måske derfor man skal beholde Genmab, eller købe inden de bliver købt
	10/11 18:12 af Bulder	I'm not worried of safety at all.
	10/11 18:10 af Bulder	Hopefully an assessment of the quality of efficacy. That's where I'm a little sceptic maybe. But we'll also soon see assessments from the medical world. Looking forward to that.
	10/11 18:10 af GeorgeBest	He says they can produce thousands of samples in the same time as competitors produce a handful!
	10/11 18:09 af GeorgeBest	Jan always points out Genmabs abilities to combine bispecific antibodies via robotics. Any idea why other Pharma companies can‘t copy?
	10/11 18:06 af AaBforever	@E L What do you expect we will hear on fridag 13.?
	10/11 18:06 af GeorgeBest	But I am sure they will deliver again
	10/11 18:06 af GeorgeBest	Yes, I must admit, I got carried away with Jans words again again...;-)
	10/11 18:02 af E L	but seriously curious what people where expecting/ why they are disapointed. We have seen these sort of early data sets many times before now, it ususally isn't more then this
	10/11 18:00 af E L	I did - and no need to say thanks.
	10/11 17:45 af gdn55	Ditto her. Tak
	10/11 17:34 af GeorgeBest	Thanks E L for the fantastic job you are doing :-)
	10/11 17:16 af E L	what is it then that you where hoping for / expecting?
	10/11 16:35 af Bulder	looks like it, both Q
	10/11 16:31 af E L	should we conclude that Colorectal cancer and Ovarian cancer will not continue to the expansion phase?
	10/11 16:25 af E L	on P20 of the presentation , fig A, the best change in SoD from baseline =-100%; does that mean the tumor disappeared?
	10/11 16:19 af peter12	ok tak ;-)
	10/11 16:15 af Bulder	det er epco Peter
	10/11 16:11 af peter12	And as disclosed in the abstract, by the time of the cut, the median follow-up was 8.3 months, and 25 patients were still ongoing. And I think that with this, I give you a signal, that 25 patients were still ongoing. And if you look at the data again at the tail, in above 48 milligrams for the DLBCL from 7 patients, the ORR was 100%; CR, 28%; 72% PRs, and those patients were ongoing. So – and the FPL, same thing, above 12. And the cut is arbitrary,
	10/11 16:10 af peter12	Judith also mentioned CR's at the cc ?
	10/11 16:06 af E L	2x NSCLC, Urothelial, Endometrial, TNBC (Triple-negative breast cancer), SCCHN ( Squamous Cell Carcinoma of the Head and Neck) and Cervical
	10/11 16:03 af E L	So on my earlier question, will they open expansion cohorts for the other diseases?' there will be 7 expansion cohorts with up to 40 patients per cohort
	10/11 15:17 af DevOp	Thx E L, now with easily read dosing.